B. Riley Predicts Cytokinetics' Q2 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Stock analysts at B. Riley upped their Q2 2025 earnings estimates for Cytokinetics in a report issued on Wednesday, May 7th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings per share of ($1.37) for the quarter, up from their prior forecast of ($1.40). The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics' Q3 2025 earnings at ($1.46) EPS, Q4 2025 earnings at ($1.42) EPS, FY2025 earnings at ($5.61) EPS, FY2026 earnings at ($5.55) EPS, FY2027 earnings at ($4.70) EPS, FY2028 earnings at ($2.53) EPS and FY2029 earnings at $0.74 EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.77 million. During the same quarter last year, the firm posted ($1.33) EPS. Cytokinetics's revenue for the quarter was up 89.1% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of Cytokinetics in a research report on Monday, April 21st. Needham & Company LLC restated a "buy" rating and issued a $72.00 price objective on shares of Cytokinetics in a research note on Wednesday. Royal Bank of Canada decreased their target price on Cytokinetics from $82.00 to $80.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Evercore ISI raised shares of Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $74.44.

Cytokinetics Stock Down 2.0%

CYTK traded down $0.61 during mid-day trading on Friday, reaching $30.00. 2,019,835 shares of the stock were exchanged, compared to its average volume of 1,672,314. Cytokinetics has a 1 year low of $29.95 and a 1 year high of $61.40. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The stock has a market capitalization of $3.58 billion, a PE ratio of -5.58 and a beta of 0.81. The company has a 50 day moving average price of $39.69 and a two-hundred day moving average price of $45.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp raised its stake in Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Cytokinetics during the 4th quarter worth $29,000. Fifth Third Bancorp lifted its holdings in shares of Cytokinetics by 42.2% during the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 291 shares during the last quarter. Parallel Advisors LLC increased its stake in Cytokinetics by 500.5% in the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 916 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Cytokinetics by 281.0% during the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 826 shares during the last quarter.

Insider Activity at Cytokinetics

In related news, EVP Andrew Callos sold 2,886 shares of the business's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $35.78, for a total transaction of $103,261.08. Following the completion of the transaction, the executive vice president now directly owns 64,689 shares in the company, valued at $2,314,572.42. The trade was a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert I. Blum sold 16,970 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.44, for a total value of $737,176.80. Following the completion of the sale, the chief executive officer now directly owns 364,181 shares in the company, valued at approximately $15,820,022.64. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 95,362 shares of company stock valued at $3,899,118. Corporate insiders own 2.70% of the company's stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.